Brind.

Recursion Pharmaceuticals stock outperformed the S&P 500 in a trading session on July 18, 2025, while the broader medical sector was experiencing losses.

1 report, 1 independent Updated Jul 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Recursion Pharmaceuticals stock outperformed the S&P 500 in a trading session on July 18, 2025, while the broader medical sector was experiencing losses.

Who's involved

What this event is mainly about
Recursion (United States)

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksRecursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.52, marking a +2.41% move from the previous day. The